Literature DB >> 23800865

Biological variability and the emergence of multidrug-resistant tuberculosis.

Tawanda Gumbo.   

Abstract

A new study demonstrates that bacterial mutation rates associated with the Mycobacterium tuberculosis lineage most commonly linked to multidrug-resistant tuberculosis are multifold higher than shown in previous studies. This discovery, when considered together with recent findings on pharmacokinetic variability in patients, leads to new models of how multidrug-resistant tuberculosis arises, with direct therapeutic implications.

Entities:  

Mesh：

Year:  2013        PMID： 23800865     DOI： 10.1038/ng.2675

Source DB:  PubMed          Journal:  Nat Genet        ISSN： 1061-4036            Impact factor:   38.330


  14 in total

1.  Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux.

Authors:  Gail E Louw; Robin M Warren; Nicolaas C Gey van Pittius; Rosalba Leon; Adelina Jimenez; Rogelio Hernandez-Pando; Christopher R E McEvoy; Melanie Grobbelaar; Megan Murray; Paul D van Helden; Thomas C Victor
Journal:  Am J Respir Crit Care Med       Date:  2011-04-21       Impact factor: 21.405

2.  Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.

Authors:  Jotam G Pasipanodya; Shashikant Srivastava; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2012-03-30       Impact factor: 9.079

3.  Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.

Authors:  Tawanda Gumbo; Chandima S W Siyambalapitiyage Dona; Claudia Meek; Richard Leff
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

4.  Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis.

Authors:  H L David
Journal:  Appl Microbiol       Date:  1970-11

5.  Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa.

Authors:  Alistair D Calver; Alecia A Falmer; Megan Murray; Odelia J Strauss; Elizabeth M Streicher; Madelene Hanekom; Thelma Liversage; Mothusi Masibi; Paul D van Helden; Robin M Warren; Thomas C Victor
Journal:  Emerg Infect Dis       Date:  2010-02       Impact factor: 6.883

6.  Variable host-pathogen compatibility in Mycobacterium tuberculosis.

Authors:  Sebastien Gagneux; Kathryn DeRiemer; Tran Van; Midori Kato-Maeda; Bouke C de Jong; Sujatha Narayanan; Mark Nicol; Stefan Niemann; Kristin Kremer; M Cristina Gutierrez; Markus Hilty; Philip C Hopewell; Peter M Small
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-13       Impact factor: 11.205

7.  Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis.

Authors:  Diana Machado; Isabel Couto; João Perdigão; Liliana Rodrigues; Isabel Portugal; Pedro Baptista; Bruno Veigas; Leonard Amaral; Miguel Viveiros
Journal:  PLoS One       Date:  2012-04-06       Impact factor: 3.240

8.  Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis.

Authors:  Christopher B Ford; Rupal R Shah; Midori Kato Maeda; Sebastien Gagneux; Megan B Murray; Ted Cohen; James C Johnston; Jennifer Gardy; Marc Lipsitch; Sarah M Fortune
Journal:  Nat Genet       Date:  2013-06-09       Impact factor: 38.330

9.  A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients.

Authors:  Jotam G Pasipanodya; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

10.  Global transcriptional profiling of longitudinal clinical isolates of Mycobacterium tuberculosis exhibiting rapid accumulation of drug resistance.

Authors:  Anirvan Chatterjee; Dhananjaya Saranath; Purva Bhatter; Nerges Mistry
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240
View more
  16 in total

1.  Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis.

Authors:  Jotam G Pasipanodya; Wynand Smythe; Corinne S Merle; Piero L Olliaro; Devyani Deshpande; Gesham Magombedze; Helen McIlleron; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

2.  Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges.

Authors:  Gesham Magombedze; Jotam G Pasipanodya; Shashikant Srivastava; Devyani Deshpande; Marianne E Visser; Emmanuel Chigutsa; Helen McIlleron; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

3.  Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.

Authors:  Devyani Deshpande; Jotam G Pasipanodya; Stellah G Mpagama; Shashikant Srivastava; Paula Bendet; Thearith Koeuth; Pooi S Lee; Scott K Heysell; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

4.  Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.

Authors:  Devyani Deshpande; Jotam G Pasipanodya; Stellah G Mpagama; Paula Bendet; Shashikant Srivastava; Thearith Koeuth; Pooi S Lee; Sujata M Bhavnani; Paul G Ambrose; Guy Thwaites; Scott K Heysell; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

Review 5.  Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis.

Authors:  Keertan Dheda; Tawanda Gumbo; Neel R Gandhi; Megan Murray; Grant Theron; Zarir Udwadia; G B Migliori; Robin Warren
Journal:  Lancet Respir Med       Date:  2014-03-24       Impact factor: 30.700

6.  Drug Degradation Caused by mce3R Mutations Confers Contezolid (MRX-I) Resistance in Mycobacterium tuberculosis.

Authors:  Rui Pi; Xiaomin Chen; Jian Meng; Qingyun Liu; Yiwang Chen; Cheng Bei; Chuan Wang; Qian Gao
Journal:  Antimicrob Agents Chemother       Date:  2022-10-03       Impact factor: 5.938

7.  Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection.

Authors:  Beatriz E Ferro; Shashikant Srivastava; Devyani Deshpande; Jotam G Pasipanodya; Dick van Soolingen; Johan W Mouton; Jakko van Ingen; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

8.  Precursor Amino Acids Inhibit Polymyxin E Biosynthesis in Paenibacillus polymyxa, Probably by Affecting the Expression of Polymyxin E Biosynthesis-Associated Genes.

Authors:  Zhiliang Yu; Chenglin Guo; Juanping Qiu
Journal:  Biomed Res Int       Date:  2015-05-21       Impact factor: 3.411

9.  Differential transcriptomic and metabolic profiles of M. africanum- and M. tuberculosis-infected patients after, but not before, drug treatment.

Authors:  L D Tientcheu; J Maertzdorf; J Weiner; I M Adetifa; H-J Mollenkopf; J S Sutherland; S Donkor; B Kampmann; S H E Kaufmann; H M Dockrell; M O Ota
Journal:  Genes Immun       Date:  2015-06-04       Impact factor: 2.676

10.  The need to accelerate access to new drugs for multidrug-resistant tuberculosis.

Authors:  Helen S Cox; Jennifer J Furin; Carole D Mitnick; Colleen Daniels; Vivian Cox; Eric Goemaere
Journal:  Bull World Health Organ       Date:  2015-05-15       Impact factor: 9.408
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.